SouthState Bank Corp lifted its position in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 4.7% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 11,861 shares of the company’s stock after acquiring an additional 534 shares during the period. SouthState Bank Corp’s holdings in Eli Lilly and Company were worth $10,909,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors have also made changes to their positions in the company. Maryland Capital Advisors Inc. bought a new position in shares of Eli Lilly and Company in the 4th quarter valued at $25,000. Osbon Capital Management LLC bought a new stake in shares of Eli Lilly and Company during the 4th quarter worth $25,000. Vermillion & White Wealth Management Group LLC boosted its stake in Eli Lilly and Company by 84.2% in the third quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock valued at $27,000 after buying an additional 16 shares in the last quarter. Basso Capital Management L.P. acquired a new stake in Eli Lilly and Company in the fourth quarter valued at about $30,000. Finally, Maseco LLP grew its position in Eli Lilly and Company by 466.7% in the first quarter. Maseco LLP now owns 34 shares of the company’s stock valued at $31,000 after acquiring an additional 28 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.
Analysts Set New Price Targets
LLY has been the subject of a number of research reports. BMO Capital Markets reissued an “outperform” rating on shares of Eli Lilly and Company in a report on Monday, June 15th. Truist Financial upped their price objective on shares of Eli Lilly and Company from $1,281.00 to $1,370.00 and gave the stock a “buy” rating in a research report on Wednesday, July 8th. Morgan Stanley increased their price objective on shares of Eli Lilly and Company from $1,344.00 to $1,347.00 and gave the company an “overweight” rating in a research note on Wednesday, July 8th. Guggenheim raised their target price on shares of Eli Lilly and Company from $1,235.00 to $1,273.00 and gave the company a “buy” rating in a research report on Monday. Finally, Barclays boosted their target price on shares of Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the stock an “overweight” rating in a research note on Monday, May 4th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus price target of $1,271.93.
More Eli Lilly and Company News
Here are the key news stories impacting Eli Lilly and Company this week:
- Positive Sentiment: Eli Lilly won full FDA approval for selpercatinib in solid tumors, a regulatory win that could support future oncology revenue and reinforces the strength of Lilly’s pipeline. Eli Lilly Wins Full FDA Approval for Selpercatinib in Solid Tumors
- Positive Sentiment: Wall Street sentiment remains constructive, with Guggenheim raising its price target on Lilly and maintaining a buy rating, while other recent reports highlighted bullish analyst views and momentum around the company’s pipeline. Eli Lilly Stock in Focus as Company Presents New Kisunla Data at AAIC Following Wave of Analyst Upgrades
- Positive Sentiment: Investors are also focused on Lilly’s obesity franchise, with articles noting that its weight-loss drugs now account for a very large share of revenue, underscoring how central that growth engine remains for the stock. Here’s How Much Eli Lilly’s Weight-Loss Drugs Are Worth to Investors
- Neutral Sentiment: Lilly has been presenting new Kisunla data at the Alzheimer’s Association International Conference, which keeps attention on its dementia pipeline but does not yet appear to have delivered a clear market-moving surprise. Eli Lilly Stock in Focus as Company Presents New Kisunla Data at AAIC Following Wave of Analyst Upgrades
- Neutral Sentiment: Commentary on whether Lilly’s shares can climb much higher has added to trading interest, but this is largely market speculation rather than a new fundamental catalyst. Is Lilly Stock On Track To Hit $2,090?
- Negative Sentiment: Despite the positive pipeline and analyst backdrop, traders are reacting to signs of weakness in LLY shares versus the broader market, suggesting some profit-taking or rotation out of the name. Eli Lilly (LLY) Stock Dips While Market Gains: Key Facts
- Negative Sentiment: One article flagged a “disturbing trend” in the billion-dollar obesity-drug market as Lilly prepares to roll out its new weight-loss pill, hinting at rising scrutiny of competition and execution risk in its most important growth category. Is This Disturbing Trend Bad News for Eli Lilly in the Billion-Dollar Obesity Drug Market?
Eli Lilly and Company Stock Down 2.3%
NYSE:LLY opened at $1,154.27 on Wednesday. The firm’s 50 day simple moving average is $1,106.93 and its 200 day simple moving average is $1,034.58. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,249.45. The company has a market cap of $1.09 trillion, a PE ratio of 41.00, a P/E/G ratio of 1.44 and a beta of 0.51.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last announced its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.97 by $1.58. The firm had revenue of $19.80 billion during the quarter, compared to analysts’ expectations of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The company’s revenue was up 55.5% on a year-over-year basis. During the same period in the prior year, the company posted $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, research analysts anticipate that Eli Lilly and Company will post 35.5 earnings per share for the current year.
Eli Lilly and Company Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 24.58%.
Eli Lilly and Company Company Profile
Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.
Featured Articles
- Five stocks we like better than Eli Lilly and Company
- Why Fastenal’s Latest Drop Could Be Its Biggest Opportunity Yet
- 3 Overlooked Energy ETFs Delivering Strong Returns and Income
- 3 Space Stocks That Could Outshine SpaceX After Its IPO
- JPMorgan’s Q2 Strength Gives the Stock Rally New Support
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
